UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Analysis of Non-linear Pharmacokinetics of P-Glycoprotein Substrates in a Microfluidic Device Using a Mathematical Model that Includes an Unstirred Water Layer (UWL) Compartment

Pharmaceutical research, 2021-06, Vol.38 (6), p.1031-1039

2021

Link zum Volltext

Verfügbarkeit prüfen

Characterization of phase I and phase II metabolism of UR-1102, a novel agent for the treatment of gout

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S29-S29

2018

Link zum Volltext

Verfügbarkeit prüfen

Collagen vitrigel promotes hepatocytic differentiation of induced pluripotent stem cells into functional hepatocyte-like cells

Biology open, 2019, Vol.8 (7)

2019

Link zum Volltext

Verfügbarkeit prüfen

Identification and structure characterization of metabolites in human plasma following a single oral administration of [14C]alectinib: Overcoming the low sensitivity levels of the conventional LC-LSC method

Drug metabolism and pharmacokinetics, 2017-01, Vol.32 (1), p.S80-S80

2017

Link zum Volltext

Verfügbarkeit prüfen

Metabolites of alectinib in human: their identification and pharmacological activity

Heliyon, 2017-07, Vol.3 (7), p.e00354-e00354, Article e00354

2017

Link zum Volltext

Verfügbarkeit prüfen

In vitro metabolism of alectinib, a novel highly potent alk inhibitor: Contribution of CYP3A enzymes in microsomes and hepatocytes

Drug metabolism and pharmacokinetics, 2017-01, Vol.32 (1), p.S80-S81

2017

Link zum Volltext

Verfügbarkeit prüfen

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Chemical and Pharmaceutical Bulletin, 2008/11/01, Vol.56(11), pp.1555-1561

2008

Link zum Volltext

Verfügbarkeit prüfen

Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout

Xenobiotica, 2021-01, Vol.51 (1), p.61-71

2021

Link zum Volltext

Verfügbarkeit prüfen

Quantitative prediction of CYP3A‐mediated drug–drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

British journal of pharmacology, 2024-04, Vol.181 (7), p.1091-1106

2024

Link zum Volltext

Verfügbarkeit prüfen

Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist

Journal of medicinal chemistry, 2020-05, Vol.63 (10), p.5089-5099

2020

Link zum Volltext

Verfügbarkeit prüfen

In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Xenobiotica, 2018-06, Vol.48 (6), p.546-554

2018

Link zum Volltext

Verfügbarkeit prüfen

Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone

The Journal of pharmacology and experimental therapeutics, 2016-04, Vol.357 (1), p.157

2016

Link zum Volltext

Verfügbarkeit prüfen

Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

Journal of medicinal chemistry, 2018-07, Vol.61 (14), p.5949-5962

2018

Link zum Volltext

Verfügbarkeit prüfen

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

Chemical and Pharmaceutical Bulletin, 2009/10/01, Vol.57(10), pp.1178-1178

2009

Link zum Volltext

Verfügbarkeit prüfen

Prediction of the pharmacokinetics of clinical candidates in humans from in vitro data

Folia Pharmacologica Japonica, 2010, Vol.135(2), pp.84-86

Nakagawa, Toshito

2010

Link zum Volltext

Verfügbarkeit prüfen

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells

International journal of oncology, 2015-04, Vol.46 (4), p.1560-1572

2015

Link zum Volltext

Verfügbarkeit prüfen

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: Optimization from lead compound to CH5137291

The Prostate, 2011-09, Vol.71 (12), p.1344-1356

2011

Link zum Volltext

Verfügbarkeit prüfen

Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer

Bioorganic & medicinal chemistry, 2010-12, Vol.18 (23), p.8150-8157

2010

Link zum Volltext

Verfügbarkeit prüfen

5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity

Journal of medicinal chemistry, 2009-07, Vol.52 (13), p.3855-3868

2009

Link zum Volltext

Verfügbarkeit prüfen

Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

Bioorganic & medicinal chemistry, 2010-05, Vol.18 (9), p.3159-3168

2010

Link zum Volltext

Verfügbarkeit prüfen

Biological Properties of Androgen Receptor Pure Antagonist forTreatment of Castration-Resistant Prostate Cancer: Optimization From Lead Compound to CH5137291

The Prostate, 2011, Vol.71 (12), p.1344-1356

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A219-A219

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A220-A220

2009

Link zum Volltext

Verfügbarkeit prüfen

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11)

Chemical & pharmaceutical bulletin, 2009-10, Vol.57 (10)

2009

Link zum Volltext

Verfügbarkeit prüfen

In vitro試験からのヒト体内動態予測

日本薬理学雑誌, 2010, Vol.135(2), pp.84-86

中川, 俊人

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(33)

Sprache

Englisch
(32)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Analysis of Non-linear Pharmacokinetics of P-Glycoprotein Substrates in a Microfluidic Device Using a Mathematical Model that Includes an Unstirred Water Layer (UWL) Compartment

Characterization of phase I and phase II metabolism of UR-1102, a novel agent for the treatment of gout

Collagen vitrigel promotes hepatocytic differentiation of induced pluripotent stem cells into functional hepatocyte-like cells

Identification and structure characterization of metabolites in human plasma following a single oral administration of [14C]alectinib: Overcoming the low sensitivity levels of the conventional LC-LSC method

Metabolites of alectinib in human: their identification and pharmacological activity

In vitro metabolism of alectinib, a novel highly potent alk inhibitor: Contribution of CYP3A enzymes in microsomes and hepatocytes

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout

Quantitative prediction of CYP3A‐mediated drug–drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist

In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone

Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

Prediction of the pharmacokinetics of clinical candidates in humans from in vitro data

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: Optimization from lead compound to CH5137291

Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer

5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity

Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

Biological Properties of Androgen Receptor Pure Antagonist forTreatment of Castration-Resistant Prostate Cancer: Optimization From Lead Compound to CH5137291

Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers

Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11)

In vitro試験からのヒト体内動態予測

Suchergebnisse filtern